There is evidence from epidemiology studies of a negative association between infection with helminth parasites and the development of allergy and asthma. Here, we demonstrate that the excretory/secretory products of the helminth Fasciola hepatica (FHES) protected mice against ovalbumin (OVA)-induced allergic asthma when administered at time of allergen sensitization. FHES reduced the accumulation of mucus, eosinophils and lymphocytes into the airways of allergen-challenged mice. Furthermore, FHES treatment suppressed Th2 responses in the airways. Interestingly, systemic administration of FHES at allergen challenge had no effect on airway inflammation, demonstrating that alum-induced Th2 response is set following initial allergen sensitization.
| INTRODUCTION
There is now convincing epidemiological evidence to suggest that helminth infections attenuate allergy. 1 Helminths exert immunoregulatory mechanisms as an immune evasion strategy to suppress the generation of protective Th2 responses. The host may also exert its own regulatory mechanisms to prevent immune-mediated pathology. 2 The combination of host-and parasite-induced immune regulation may explain how helminth infections can protect against allergy.
Infection with Nippostrongylus brasiliensis, Schistosoma mansoni, Schistosoma japonicum, Litomosoides sigmodontis and
Heligmosomoides polygyrus has all been shown to suppress the development of experimental allergic asthma. [3] [4] [5] [6] The protective effect of H. polygyrus and L. sigmodontis infection against allergic airway inflammation was both reversed upon depletion of Treg cells,
highlighting Treg cells as a mediator of helminth-induced immunoregulation. 3, 5 These experimental and epidemiological studies have led to exploratory clinical trials with helminth-based therapy in humans. However, to date these trials have not demonstrated a protective effect against allergic disease 7, 8 and are complicated by logistic and safety issues around to use of live parasites/eggs as a therapeutic approach for human diseases. An alternative approach is to use helminth-derived products, which can mimic the immunomodulatory effect of infection. The secreted products of H. polygyrus, and N. brasiliensis and the total antigen of Ascaris sunum have been shown to suppress allergic airway inflammation. [9] [10] [11] [12] Individual recombinant helminth proteins have also been shown to be beneficial against experimental allergic asthma.
11,13
We have previously demonstrated infection with the liver fluke 
| MATERIALS AND METHODS

| Mice
| Preparation of FHES
Live adult flukes were collected from infected bovine livers at a local abattoir, washed with PBS containing 100 μg/mL penicillin and streptomycin. Live flukes were incubated overnight in PBS at 37°C and 5% CO 2 . The supernatant was harvested, centrifuged at 13 000 g for 30 minutes, filtrated through a 0. 
| RESULTS
| FHES ameliorates OVA-induced allergic asthma when given at time of allergen sensitization
We investigated the effect of FHES on allergic responses using the OVA-induced allergic asthma model, where mice were sensitized to OVA by immunization with OVA adjuvanted with alum followed by challenge with aerosolized OVA (Fig. S1A ). Challenged mice devel- Student's t test. *P < .05 **P < .01 ***P < .001
BAL fluid of OVA-challenged mice ( Figure 1A ). There was a significant reduction in the numbers of eosinophils and lymphocytes in the BAL ( Figure 1A ). In contrast, FHES had no suppressive effect on OVAspecific IgG 1 or IgE in the BAL (Fig. S2A) or serum (Fig. S2B) , or on total IgG 1 or IgE in the serum (Fig. S2C) . Administration of FHES enhanced OVA-specific IgE in the BAL (Fig. S2A ) and total IgE in the serum ( following allergen challenge ( Figure 2B ). These data demonstrate that although FHES given at sensitization did not inhibit OVA-specific antibody, it did inhibit lung inflammation, Th2 cytokines and eosinophilic infiltration into the lung following allergen challenge.
| FHES inhibits dendritic cell function, but has no effect on inflammasome-dependent immune responses
Alum activates the NLRP3 inflammasome, which mediates some of its adjuvant properties. [16] [17] [18] IL-1 signalling has been shown to be important for induction of airway inflammation in the alum-OVA allergy model. 19 This raises the possibility that FHES might directly inhibit inflammasome-dependent IL-1β release. However, we found that FHES had no effect on inflammasome-dependent IL-1β production from macrophages induced by alum or MSU in combination with LPS (Fig. S5A) . Furthermore, we found that FHES did not inhibit neutrophil or macrophage recruitment in an inflammasome-dependent sterile peritonitis model induced by injection with MSU 20 (Fig. S6A ).
FHES has previously been shown to inhibit the maturation and
APC function of dendritic cells (DC)
. [21] [22] [23] We found that FHES inhibited LPS-induced production of IL-12p70 and IL-23 by bone marrowderived DC (BMDC) (Fig. S6A) . Moreover, FHES reduced LPS-induced expression of CD40, CD80 and MHC-II on DCs (Fig. S6B) . As FHES
inhibited DC maturation, we tested its effect on APC function. Bone marrow-derived DC, loaded with OVA as an antigen, and incubated with either PBS, FHES, LPS or FHES and LPS, were adoptively transferred into BALB/c mice. We found that treating LPS-activated BMDC with FHES, prior to adoptive transfer, reduced the ability of these cells to induce cytokine production by OVA-specific T cells following ex vivo antigen restimualtion of LN cells on day 7 post-transfer.
Interestingly, there was a significant reduction in the production the Th2 effector cytokines IL-5 and IL-13 as well as IFN-γ.
| FHES has no effect on OVA-induced allergic asthma when given during allergen challenge
Several studies that have demonstrated a beneficial effect of helminth products in experimental allergy administered these products only at the initial allergen sensitization. 6, 9, 24 Evidence of a protective effect of helminth products given at allergen challenge is less clear. Thus, we investigated the efficacy of FHES given systemically during allergen challenge, as a positive treatment control, another group were given FHES at sensitization only ( 
| DISCUSSION
This study demonstrates that the soluble products of F. hepatica blocked the development of OVA-induced allergic asthma.
Administration of FHES at sensitization, but not at allergen challenge, The fact that FHES failed to attenuate allergic responses when given at challenge is a limitation of our study. Indeed, this lack of efficacy after the allergen-sensitization phase appears to be a common feature of other helminth/helminth products; McSorley et al 24 reported that H. polygyrus ES had a very limited effect on airway hypersensitivity (AHR) and type 2 responses when given at challenge.
Likewise, N. brasiliensis ES inhibited the induction of AHR when given
at sensitization but not when given 7 days later. 9 Furthermore, infection with N. brasiliensis prior to but not after allergen sensitization blocked lung eosinophilia. 6 These studies suggests that alum-induced allergic responses are largely set following initial sensitization and that prior exposure to helminth products is required for effective helminth therapy. Since many published studies have examined the effect of helminth infection/products on AHR at allergen sensitization only, these studies have thus assessed the effect of helminth products on the alum-mediated induction of Th2 cells that drive allergy rather than established allergic responses.
In our previous study of the effect of FHES on autoimmunity, we demonstrated that FHES promoted F. hepatica-specific Th2 responses in vivo, and on the face of it, this appears to be difficult to reconcile with its ability to inhibit allergic sensitization. 15 However, similar to our findings, the ES products of N. brasiliensis which inhibited
OVA-alum-induced allergic inflammation also induced Th2 responses
to its own antigens, 9 suggesting that induction of a parasite-specific is much diminished in IL-1-deficient mice. 19 Given the evidence that the inflammasome plays a role in alum adjuvanticity, we hypothesized that FHES would inhibit inflammasome activation. In contrast,
we found that FHES did not inhibit inflammasome-dependent IL-1β production in vitro, or neutrophil recruitment in vivo. The specific role of the inflammasome in mediating alum adjuvanticity is complex; for instance, it is required for the production of IgE, 16 responses to its own antigens in vivo. 15 Thus, the inhibitory effect of FHES on DC may represent a mechanism by which FHES inhibits allergic sensitization.
We have previously shown that FHES induces the release of IL-33 in vivo in C57BL/6 mice, which promotes eosinophilia that was required for its protective effect in EAE. 15 In contrast, the present study showed that FHES blocked allergic eosinophilia. However, in the OVA-induced allergic asthma model, eosinophils are essentially a readout of Th2 cell activity in the allergen-challenged lung; thus, we have shown that FHES blocks alum-induced Th2 cell induction rather than directly inhibiting eosinophils. In fact, it is likely that FHES recruits eosinophils to the injection site during allergen sensitization. The effect of FHES-recruited eosinophils on allergic sensitization has not been examined. IL-33 is widely considered to be an exacerbating factor in allergy and asthma, 28 where it plays activates type 2 responses during early allergen sensitization. 29 Indeed, alum induces IL-33 production in vivo. 30 Oboki et al 31 demonstrated that IL-33-deficient mice are resistant to OVA-induced allergic asthma. However, that study also found that C57BL/6 mice are more responsive to IL-33 than BALB/c mice, the mice we used in the present study. 31 Therefore, it is possible that FHES-induced IL-33 may play less of a role in BALB/c mice.
The method of allergen sensitization appears to have an effect on the requirement of IL-33 in this model; genetic ablation of ST2 (IL33R) did not diminish allergic responses in mice that were sensitized twice with alum and OVA. 32, 33 In contrast, ST2 was shown to play a role in allergic responses in mice that were immunized once. 34 As we immunized twice, this may explain the lack of an effect of FHES-induced IL-33 on allergic sensitization. This suggests that IL-33 has a less potent effect on established antigen-specific immune responses than it does upon early development of antigen specificity. Consistent with this view, alum-induced IL-33 was found to be required for the early alum-induced cytokine responses, but ultimately had no impact on later alum-induced antigen-specific T cells/antibody responses. 30, 31 In summary, our study shows that the secreted products F. hepatica inhibit allergic sensitization induced by alum and thus may be a potential source of immunomodulatory molecules.
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